Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 1/20 | 0.36 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.36 |
| ▸ | KIT | P10721 | 1/20 | 0.36 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.36 |
| ▸ | FLT3 | P36888 | 1/20 | 0.36 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 2/20 | 0.35 |
| ▸ | IDO1 | P14902 | 2/20 | 0.35 |
| ▸ | CDC7 | O00311 | 1/20 | 0.34 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5413218 | 0.84 | PDE5A (0.32) | IDO1TSHRLMNATP53AURKA | |
| SCHEMBL5417036 | 0.83 | KDR (0.33) | KITUSP2AURKARPS6KB1 | |
| SCHEMBL3694486 | 0.81 | HTR2C (0.34) | IDO1CDC7DBF4CYP1A2CYP3A4 | |
| SCHEMBL5405596 | 0.81 | IDO1 (0.33) | EGFRIDO1CDC7DBF4AURKA | |
| SCHEMBL5414191 | 0.80 | KMT2A (0.35) | AURKARPS6KB1 | |
| SCHEMBL5415909 | 0.78 | NAE1 (0.39) | EGFRTSHRLMNAMAPK1MAP2K7 | |
| SCHEMBL5409941 | 0.78 | MPO (0.34) | EGFR | |
| SCHEMBL6932971 | 0.76 | KDM4E (0.34) | TSHRLMNATP53AURKARPS6KB1 | |
| SCHEMBL5407765 | 0.76 | ELOVL1 (0.34) | IDO1AURKARPS6KB1AURKBMAOB | |
| SCHEMBL5417048 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7291730-B2 | Pyrimidine compounds and their use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-11-06 | — | — | US | disclosed |
| US-20050107609-A1 | Pyrimidine compounds and their use | SUMITOMO CHEMICAL COMPANY | 2005-05-19 | — | — | US | disclosed |
| US-6838463-B2 | Pyrimidine compounds and their use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-01-04 | — | — | US | disclosed |
| EP-1366026-B1 | PYRIMIDINE COMPOUNDS AND THEIR USE AS PESTICIDES | SUMITOMO CHEMICAL CO (JP) | 2004-12-01 | — | — | EP | disclosed |
| US-20040077669-A1 | Pyrimidine compounds and their use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2004-04-22 | — | — | US | disclosed |
| EP-1366026-A2 | PYRIMIDINE COMPOUNDS AND THEIR USE | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2003-12-03 | — | — | EP | disclosed |
| WO-2002024663-A2 | PYRIMIDINE COMPOUNDS AND THEIR USE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107609-A1 | Pyrimidine compounds and their use | TYMP, TYMS, UMPS | CSF1R 3158/4885PDGFRB 473/4885KIT 1358/4885 |
| US-20040077669-A1 | Pyrimidine compounds and their use | TYMP, TYMS, DPYD | CSF1R 3519/4885PDGFRB 358/4885KIT 1274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.